ArticleJournal of Alzheimer's disease : JAD2021
ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.
Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Risk factors underlying brain structure change rate in cognitive decline: Results from genomewide and phenomewide investigations.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- A new ANMerge-based blood transcriptomic resource to support Alzheimer's disease research.medRxiv : the preprint server for health sciences · 2025Article
- Novel set of plasma proteins classifies Alzheimer's dementia in African American individuals with high accuracy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Predicting Alzheimer's disease subtypes and understanding their molecular characteristics in living patients with transcriptomic trajectory profiling.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Nomination of a novel plasma protein biomarker panel capable of classifying Alzheimer's disease dementia with high accuracy in an African American cohort.bioRxiv : the preprint server for biology · 2024Article
- Disentangling Accelerated Cognitive Decline from the Normal Aging Process and Unraveling Its Genetic Components: A Neuroimaging-Based Deep Learning Approach.Journal of Alzheimer's disease : JAD · 2024Article
- Semantic Harmonization of Alzheimer's Disease Datasets Using AD-Mapper.Journal of Alzheimer's disease : JAD · 2024Article
- Multimodal Alzheimer's disease classification through ensemble deep random vector functional link neural network.PeerJ. Computer science · 2024Article
- Artificial intelligence for dementia genetics and omics.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Review
- CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting.Journal of Alzheimer's disease : JAD · 2023Review
- Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.Alzheimer's research & therapy · 2022Article
- Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer's disease.Nature communications · 2022Article
- ADataViewer: exploring semantically harmonized Alzheimer's disease cohort datasets.Alzheimer's research & therapy · 2022Article
- Comparison and aggregation of event sequences across ten cohorts to describe the consensus biomarker evolution in Alzheimer's disease.Alzheimer's research & therapy · 2022Article
- Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data-driven disease modeling.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Machine learning based multi-modal prediction of future decline toward Alzheimer's disease: An empirical study.PloS one · 2022Article
- Evaluating the Alzheimer's disease data landscape.Alzheimer's & dementia (New York, N. Y.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAccessible datasets are of fundamental importance to the advancement of Alzheimer's disease (AD) research. The AddNeuroMed consortium conducted a longitudinal observational cohort study with the aim to discover AD biomarkers. During this study, a broad selection of data modalities was measured including clinical assessments, magnetic resonance imaging, genotyping, transcriptomic profiling, and blood plasma proteomics. Some of the collected data were shared with third-party researchers. However, this data was incomplete, erroneous, and lacking in interoperability.
objectiveTo provide the research community with an accessible, multimodal, patient-level AD cohort dataset.
methodsWe systematically addressed several limitations of the originally shared resources and provided additional unreleased data to enhance the dataset.
resultsIn this work, we publish and describe ANMerge, a new version of the AddNeuroMed dataset. ANMerge includes multimodal data from 1,702 study participants and is accessible to the research community via a centralized portal.
conclusionANMerge is an information rich patient-level data resource that can serve as a discovery and validation cohort for data-driven AD research, such as, for example, machine learning and artificial intelligence approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.